Search

USPTO Patent Grant US12583844B2: Hydantoin MMP Inhibitors

The USPTO has granted patent US12583844B2 to Foresee Pharmaceuticals USA, Inc. for hydantoin-based compounds that act as inhibitors of matrix metalloproteinases (MMPs), particularly MMP-12. The patent covers compositions and methods for treating various diseases mediated by MMP-12.

USPTO Patent Grant for Trinucleotide Repeat Disease Treatment

The USPTO has granted a patent (US12583845B2) to The Research Foundation for The State University of New York for compositions and methods to treat diseases involving trinucleotide repeats. The patent covers novel compounds and synthesis processes aimed at inhibiting microsatellite promoted expression of deleterious expansions.

Omecamtiv Mecarbil Salt and Preparation Process

The USPTO has granted US Patent 12583821B2 to Cytokinetics, Inc. for a specific salt form of omecamtiv mecarbil and its preparation process. This patent covers the dihydrochloride salt form, related compositions, and methods of use, primarily impacting pharmaceutical development and intellectual property.

USPTO Patent Grant: Benzopyran Derivatives as CRAC Inhibitors

The USPTO has granted a patent (US12583846B2) for benzopyran derivatives identified as CRAC inhibitors. The patent, filed on September 25, 2020, covers compounds represented by a specific formula, isomers, or pharmaceutically acceptable salts thereof, and their application in preparing CRAC inhibitors.

USPTO Patent Grant: Benzylamine Derivative for Anti-Tumor Efficacy

The USPTO has granted a patent (US12583822B2) to the Academy of Military Medical Sciences for a benzylamine derivative with potential anti-tumor efficacy. The patent covers the derivative, its preparation method, and its use in treating PD-1/PD-L1-related diseases.

USPTO Patent Grant for Fluorinated Pyrimidine Compound Production

The USPTO has granted a patent (US12583847B2) to UNIMATEC CO., LTD. for a fluorinated pyrimidine compound and its production method. The patent covers specific chemical structures and synthesis processes, with a filing date of March 16, 2022.

USPTO Patent US12583848B2: Isoxazole Derivatives for Viral Infections

The USPTO has granted patent US12583848B2 to Universitätsklinikum Jena for isoxazole-3-carboxamide derivatives used in treating viral infections. The patent describes compounds effective against various viruses, including resistant strains, with low induction of cytochrome P4503A4.

USPTO Patent US12583849B2 for KCNT1 Inhibitors

The USPTO has granted patent US12583849B2 to PRAXIS PRECISION MEDICINES, INC. for KCNT1 inhibitors and methods of use. This patent covers compounds and compositions for treating neurological diseases, conditions related to excessive neuronal excitability, and gain-of-function mutations in genes like KCNT1.

USPTO Patent US12583820B2: Antivirals against coronavirus

The USPTO has granted patent US12583820B2 to Kansas State University Research Foundation for broad spectrum antivirals against coronaviruses. The patent covers specific chemical compounds designed to inhibit viral replication.

Biomaterial with functionalized tyrosine, preparation method, pharmaceutical composition

The USPTO has granted a patent (US12583818B2) for a method to prepare a biomaterial with selectively functionalized tyrosine and a pharmaceutical composition containing it. This innovation aims to improve the efficacy of biomaterial drugs by ensuring selective coupling to tyrosine without affecting other amino acids or the biomaterial's inherent activity.

USPTO Patent Grant US12582652B2 for Ion Channel Modulator

The USPTO has granted patent US12582652B2 to Praxis Precision Medicines, Inc. for a novel ion channel modulator compound. The patent covers methods of treating neurological disorders and conditions associated with neuronal excitability.

USPTO Patent Grant: Chemokine CXCR4 Receptor Modulators

The USPTO has granted a patent to Emory University for chemokine CXCR4 receptor modulators and their uses. The patent covers compounds and pharmaceutical compositions that can be used for managing various conditions including viral infections, abnormal cellular proliferation, and cancer.

USPTO Patent Grant: Pyrazine Derivatives for Pest Control

The USPTO has granted patent US12583851B2 to Elanco Animal Health GmbH for novel heteroaryl-substituted pyrazine derivatives. These compounds are intended for controlling animal pests, arthropods, insects in plant protection, and ectoparasites on animals.

USPTO Patent Grant: Heterocycle Derivative for Hair Loss Therapy

The USPTO has granted patent US12583852B2 for a novel heterocycle derivative, assigned to JW PHARMACEUTICAL CORPORATION. This patent covers compounds effective for the therapy and prevention of hair loss, including androgenic alopecia and alopecia areata.

USPTO Patent US12583840B2 for Androgen Receptor Antagonists Preparation

The USPTO has granted patent US12583840B2 to Orion Corporation for a method of preparing androgen receptor antagonists and their intermediates. The patent details a process using a heterogeneous palladium catalyst for the preparation of a specific benzonitrile compound useful in the synthesis of carboxamide-structured androgen receptor antagonists.

USPTO Patent Grant for BCL-2 Inhibitors

The USPTO has granted a patent (US12583853B2) to Newave Pharmaceutical Inc. for 1H-pyrrolo[2,3-b]pyridine derivatives and related compounds as BCL-2 inhibitors. These compounds are intended for the treatment of neoplastic and autoimmune diseases.

Amgen KRAS G12C Inhibitors Patent Granted

The USPTO has granted Amgen Inc. a patent (US12583854B2) for KRAS G12C inhibitors and methods of using them to treat cancers. The patent covers compositions and methods for treating pancreatic, colorectal, and lung cancers.

USPTO Patent US12583857B2 for Anti-liferative Agents

The USPTO has granted patent US12583857B2 for anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines. The patent was granted to PHEON THERAPEUTICS LTD and covers compounds useful as medicaments, particularly as anti-proliferative agents.

Redona Therapeutics Cancer Treatment Compounds Patent Grant

The USPTO has granted Redona Therapeutics, Inc. a patent (US12583825B2) for novel cancer treatment compounds. The patent covers specific benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives and their use in treating neoplastic diseases.

Genentech, Inc. Granted Patent for TDO2 Inhibitors

The USPTO has granted Genentech, Inc. patent US12583858B2 for TDO2 inhibitors. These inhibitors are useful for modulating tryptophan 2,3 dioxygenase activity, treating immunosuppression, and enhancing anti-cancer treatments. The patent was filed on October 12, 2020.

USPTO Patent Grant US12583831B2 for Hydrogenation Processes

The USPTO has granted patent US12583831B2 to Archer-Daniels-Midland Company for selective hydrogenation processes and catalysts. The patent covers methods for upgrading impure feedstocks, such as those derived from biomass, to increase the concentration of valuable intermediates like glycolaldehyde and hydroxyacetone.

USPTO Patent Grant: Process for Ethyleneamines and Ethanolamines Manufacture

The USPTO has granted patent US12583827B2 to BASF SE for a new process to manufacture ethyleneamines and ethanolamines. The patent details a two-step process involving the conversion of glycolaldehyde derivatives and an aminating agent, followed by hydrogenation.

HSA Seized Over 1 Million Illegal Health Products in 2025

Singapore's Health Sciences Authority (HSA) reported seizing over 1 million illegal health products in 2025, a 10% increase from the previous year. The agency also removed 2,358 online listings, a significant decrease from previous years due to increased surveillance and collaboration with platforms. The enforcement actions targeted cough syrups, sexual enhancement medicines, and sedatives.

WHO Recommends New Diagnostic Tools for Tuberculosis

The World Health Organization (WHO) has issued new guidelines recommending innovative diagnostic tools for tuberculosis (TB), including near-point-of-care tests and tongue swabs. These recommendations aim to accelerate diagnosis, reduce costs, and expand access to lifesaving services, particularly in resource-constrained settings.

FDA Extends Coral Snake Antivenin Expiration Date

The FDA has extended the expiration date for Lot CL6814 of Antivenin (Micrurus fulvius) (Equine Origin), commonly known as North American Coral Snake Antivenin, from June 30, 2025, to June 30, 2026. This extension is based on stability data indicating the lot will maintain potency for an additional year.

ANSM Safety Alert: Kwik-Stik and Lyfo Disk Campylobacter jejuni Controls

The French National Agency for Medicines and Health Products Safety (ANSM) has issued a safety alert regarding bacteriology controls for Kwik-Stik and Lyfo Disk Campylobacter jejuni products from Microbiologics. This notice informs laboratories of a security action implemented by the manufacturer.

ANSM Safety Alert: Manual Ventilator

The French ANSM has updated a safety alert regarding manual ventilators (Bavu) manufactured by Intersurgical. This update expands the scope of devices affected by a previous safety action initiated in May 2025, with users receiving updated correspondence.

ANSM Safety Information: Urology/Gynecology Suction Device

The French ANSM has been informed of a lot recall initiated by Clinical Innovations, LLC for their KIWI Omni Vacuum Delivery System suction device. This safety action is registered under number R2607844 and is directed at pharmacies and healthcare facilities.

MHRA Phases Out Animal Testing with Early Data Review

The MHRA is phasing out animal testing by offering early reviews of non-animal data for drug marketing applications. This initiative aims to boost developer confidence in New Approach Methodologies (NAMs) and support the government's strategy to reduce animal use in research, while maintaining rigorous safety and efficacy standards.

MHRA Field Safety Notices for Medical Devices (March 16-20, 2026)

The MHRA has published a list of seven Field Safety Notices (FSNs) related to medical devices issued between March 16 and March 20, 2026. These notices are published for informational purposes, and recipients are advised to act on any FSN received from a manufacturer.

Hibiwash Recalled Due to Microbial Contamination

The MHRA has issued a precautionary recall for three batches of Hibiwash, an antimicrobial wash, due to microbial contamination identified at the manufacturing facility. Mölnlycke Health Care is advising healthcare professionals and retailers to stop supplying the affected batches and patients to stop using them.

DEA Phoenix Seizes 3 Million Fentanyl Pills in Arizona

The DEA Phoenix Division announced the seizure of nearly three million fentanyl pills in Arizona as part of Phase II of Operation FentanylFreeAmerica. This significant bust highlights ongoing efforts to combat the flow of illicit synthetic opioids.

DEA Memphis Arrests and Seizures

The DEA announced significant arrests and seizures in Memphis, Tennessee, including fentanyl, cocaine, meth, and numerous firearms. Administrator Cole provided remarks on the operation's success in combating drug trafficking and enhancing public safety.

DEA Omaha Seizes 70 Pounds of Methamphetamine

The DEA's Omaha Division announced the seizure of 70 pounds of methamphetamine. This action highlights ongoing efforts by law enforcement agencies to combat illicit drug trafficking.

USPTO Patent Grant: RAS Oncoprotein Inhibitors

The USPTO has granted patent US12582660B2 to the University of Louisville Research Foundation, Inc. for inhibitors of the RAS oncoprotein, methods of making, and methods of use thereof. The patent covers compounds useful in treating diseases associated with activating mutations in RAS, particularly cancer.

USPTO Patent Grant: Modified Plasma Clotting Factor VIII

The USPTO has granted patent US12583907B2 to AAVnerGene, INC. for modified human factor VIII polypeptides with enhanced activity. These polypeptides and their encoding viral vectors are intended for treating FVIII deficiencies, such as hemophilia A.

USPTO Patent US12583917B2: IL17A Antibodies for Veterinary Use

The USPTO has granted patent US12583917B2 to Elanco US Inc. for IL17A antibodies and antagonists intended for treating conditions in animals, including companion animals. The patent details specific antibody embodiments and IgG Fc variant polypeptides designed to reduce immune responses.

USPTO Patent Grant for T Cell Antigen Receptor Complex

The USPTO has granted patent US12583910B2 to Tsinghua University for a T cell antigen receptor complex and its preparation method. This patent covers antibodies, T cell receptors, and immune cells designed to recognize pMHC complexes and activate T cells for therapeutic use.

USPTO Patent Granted for Anti-Pro/Latent Myostatin Antibodies

The USPTO has granted a patent (US12582712B2) to Scholar Rock, Inc. for a method of making anti-pro/latent myostatin antibodies. The patent covers antibodies that specifically bind proMyostatin and/or latent Myostatin and their uses.

USPTO Patent Grant: Antibody Inhibitors for Staphylococcus Aureus Treatment

The USPTO has granted patent US12583913B2 for antibody inhibitors targeting Staphylococcus aureus, specifically coagulases SC and vWbp. This patent covers therapeutic methods and detection techniques utilizing these monoclonal antibodies.

USPTO Patent Grant for Cancer Diagnosis using Anti-BAG2 Antibody

The USPTO has granted a patent (US12583915B2) to Medpacto, Inc. for methods of diagnosing cancer using an anti-BAG2 antibody. The patent covers compositions comprising antibodies that specifically bind to BAG2 polypeptides or fragments thereof.

USPTO Patent Grant for LRP6 Protein Binding Antibodies

The USPTO has granted a patent (US12583919B2) to Antlera Therapeutics Inc. for antibodies that specifically bind to LRP6 proteins and methods of their use. The patent was filed on August 14, 2020, and is set to be granted on March 24, 2026.

USPTO Patent Grant for Caged-Degron Molecular Feedback Circuits

The USPTO has granted patent US12583896B2 to The Regents of the University of California for caged-degron-based molecular feedback circuits. The patent covers methods of modulating signaling pathways in cells using these circuits, with a filing date of January 6, 2020.

USPTO Patent Grant: DNA-binding domain transactivators

The USPTO has granted a patent (US12583902B2) to the University of Massachusetts for DNA-binding domain transactivators and their uses. The patent covers recombinant adeno-associated viruses (rAAVs) designed to modify target gene expression in cells.

USPTO Grants Patent for Anti-CD73 Antibody and Use

The United States Patent and Trademark Office (USPTO) has granted patent US12583933B2 to BIOTHEUS INC. for an anti-CD73 antibody and its use in enhancing immune response and treating tumors. The patent was filed on August 28, 2020, and is effective March 24, 2026.

USPTO Patent Grant for Tumor Diagnosis and Treatment

The USPTO has granted patent US12583937B2 to Genentech, Inc. for compositions and methods related to the diagnosis and treatment of tumors in mammals. The patent, filed on March 16, 2022, includes 6 claims.

Bi-specific Peptides for Cancer Treatment Granted Patent

The USPTO has granted a patent (US12583888B2) to the University of Tartu for bi-specific peptides designed to target cancer cells and the extracellular matrix. These peptides bind to fibronectin extra domain B (FN-EDB) and/or tenascin-C C domain (TNC-C). The patent was granted on March 24, 2026.

Mutant Myocilin Disease Model Patent Granted

The USPTO has granted Regeneron Pharmaceuticals, Inc. a patent (US12582104B2) for a mutant myocilin disease model. This patent covers non-human animal models engineered to express human myocilin, intended for assessing therapeutic reagents for glaucoma.

Amgen Inc. Patent for KRAS G12C Inhibitor Cancer Therapy

The USPTO has granted Amgen Inc. a patent (US12582657B2) for a combination therapy involving a KRAS G12C inhibitor and other agents for treating cancers. The patent covers pharmaceutical compositions and methods of treatment.

USPTO Patent Grant US12583892B2: Conus Peptides for Neurodegenerative Conditions

The USPTO has granted patent US12583892B2 to Technion Research and Development Foundation Limited for modified Conantokin peptides and their use in treating neurodegenerative conditions. The patent covers specific peptide forms, nucleic acids encoding them, and compositions for modulating NMDA receptors.